Kjellson Nina S 4

What Happened Nina S. Kjellson, a director of Eloxx Pharmaceuticals, received a derivative award on 2026-06-08 covering 13,587 shares. The filing reports the acquisition price as $0.00 (no immediate cash paid) and classifies the grant as an award/derivative rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-08; filing date: 2026-06-10 (timely Form 4 filing).
• Amount: 13,587 derivative shares acquired; reported price per share: $0.00 (total reported cash value $0).
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: The stock option vests in 24 substantially equal monthly installments and will be fully vested and exercisable on the second anniversary of the grant date, subject to continuous service.
• Transaction code: A = Award/Grant (derivative).

Context This was a compensation-related option grant, not a market purchase or sale. The award vests gradually over two years; the shares or option rights are not fully exercisable until vesting conditions are met. Such grants are common for directors as part of pay and do not by themselves indicate immediate buying or selling intent.